Pot Stocks Gain After Tilray Gets U.S. Approval to Import Medical Marijuana
This article is for subscribers only.
Tilray Inc. is setting a record high -- again.
Shares rose as much as 28 percent to $153.88 as of 1:35 p.m. in New York after the British Columbia-based cannabis company received approval from the U.S. government to import medical cannabis into the country for a clinical trial. The gain added nearly $3 billion to Tilray’s valuation, pushing it above $14 billion to top peer Canopy Growth Corp. and making it the largest cannabis company.